ADMA— AI Stock Forecast & Price Targets
Published 7/2/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live ADMA price forecast →
ADMA Biologics presents a classic value-vs-overhang setup: genuine operational strength (43% ROE, 70.5% Q1 gross margin, $55.7M quarterly FCF) trading at 8.6x forward earnings after a -52% YTD drawdown driven by a June 2026 securities lawsuit alleging revenue inflation. With a binary Aug 5 earnings print 34 days out, sequential Q4→Q1 revenue softness ($139M→$114M), and prior EPS/sales surprises of -11.7%/-18.2%, the operational thesis has cracks that the market is punishing appropriately. Hold with tight discipline into the print — cheap on paper, but legal and execution risk dominate.
Into the Aug 5 earnings print (34 days), stance is HOLD/do-not-chase. The $8.00-$8.10 support has held through multiple retests and is the line of defense; a decisive break there opens $7.21 and likely a fresh leg lower. Upside is capped by $10.25 resistance which has not been reclaimed. Do NOT size a swing trade into the print — it is binary with lawsuit-related commentary risk on top of normal earnings variance. If already long, consider trimming into any $9.50-$10.00 bounce ahead of the print to reduce gap risk. Invalidation for any tactical long: close below $7.90.
Over 1-6 months the thesis hinges on two catalysts: (1) the Aug 5 print — specifically whether revenue re-accelerates from the $114.5M Q1 base and whether management addresses any accounting review; and (2) legal progression — motion-to-dismiss ruling, settlement talks, or SEC involvement. A clean print plus lawsuit containment could support a re-rating toward $11-12 (still well below the $17.75 sell-side consensus but a realistic first step). A miss or restatement risk crystallizing sends the stock to fresh lows in the $6-7 range. Expected return range: -25% to +30%. Mind-changer bear-side: any 8-K disclosing accounting review; mind-changer bull-side: reaffirmed guidance with Q2 revenue back above $130M.
Over 1-3 years, if ADMA proves the ASCENIV margin structure is durable (gross margin holding 65%+), grows the S. pneumonia hyperimmune pipeline, and puts the legal overhang cleanly behind it, the current 8.6x forward P/E is unjustified for a business generating 43% ROE. A re-rate to 15-18x forward earnings on a ~$1.20-1.40 EPS run-rate implies a $18-25 range — but this requires legal resolution without material restatement AND continued execution. The biggest structural risk is that plasma-derived therapeutics face longer-term substitution risk from recombinant/synthetic alternatives, and any credibility damage from the lawsuit permanently compresses the multiple even if operations recover. Not a buy-and-forget name; requires active monitoring.
The reported quality metrics are strong on the surface: TTM ROE of 43.3%, ROA of 22%, gross margin expanding from 55.1% in Q2 2025 to 70.5% in Q1 2026, and operating margin of 43.9% in Q1 — all driven by ASCENIV mix shift. Q1 2026 delivered $114.5M revenue, $45.3M net income (39.6% net margin), and $55.7M free cash flow, with cash growing to $138.2M and stockholders' equity to $390.3M. However, three yellow flags demand caution: (1) sequential revenue declined from $139.2M in Q4 2025 to $114.5M in Q1 2026 (-17.7%), an unusual pattern for a growth story; (2) recent EPS/sales surprises of -11.7%/-18.2% show execution has already slipped versus consensus; (3) most critically, a securities lawsuit alleges revenue inflation — if any restatement emerges, the entire margin/FCF narrative is compromised. The debt figures in the snapshot are internally inconsistent (Debt/Eq 0.52 on one line, $97.7B total debt on another — clearly a data artifact; the balance sheet shows a manageable $204M total debt). Capital allocation is self-funded growth with no dividend; no evidence of buybacks despite the price collapse, which is itself a signal.
The multi-timeframe picture is broken. On the weekly chart the stock has crashed from a $23+ peak to $8.68, a ~63% peak-to-trough decline, and now sits 38.5% below its SMA200 and 57.9% below the 52-week high. The daily chart shows a violent post-earnings gap down in late March 2026 and a subsequent grind lower into the $7.20-$8.00 zone that has held as support through multiple retests. The 1h chart shows a modest recovery attempt with price reclaiming the $8.60s and now sitting +2.8% above SMA20 but still -2.9% below SMA50 — a bounce, not a reversal. RSI at 51 is neutral. The forecast band on the 1d and 4h charts projects meaningful upside into the $12-18 range, but the calibration data (daily MAPE 59%, directional accuracy at the naive baseline) makes those algorithmic targets unreliable and I discount them heavily. Key levels: support $8.00-$8.10 (held repeatedly), then $7.21 (52-week low); resistance $10.25 (recent supply), then $13.55. Until $10.25 is reclaimed on volume, the trend is down.
The dominant signal is the June 20, 2026 federal securities lawsuit alleging revenue inflation — this is the reason the stock trades where it does and why forward P/E of 8.6 has not attracted decisive buying. Offsetting that, Raymond James resumed coverage on June 10 (the piece notes 121% implied upside from analyst targets, consistent with the $17.75 consensus target), which suggests at least some institutional analysts view the legal risk as containable. The daily trading-action headlines (Zacks up/down day pieces) are pure noise. The broader market context — crypto selloffs, commodity price stories — is irrelevant to this name. Net: one existential negative catalyst, one modest positive re-engagement signal, and a binary Aug 5 earnings print that will either validate or further impair the operational narrative.
- ASCENIV IVIG margin expansion — gross margin scaled from 55.1% (Q2 2025) to 70.5% (Q1 2026), premium pricing for specialty PI indication
- S. pneumoniae hyperimmune globulin pipeline targeting immunocompromised patients — early-stage but differentiated unmet-need opportunity
- Vertical integration via owned plasma collection centers securing supply for BIVIGAM and ASCENIV, insulating from third-party plasma cost inflation
- Sell-side re-engagement (Raymond James coverage resumption on June 10, 2026) could catalyze institutional inflows if Aug print is clean
- Self-funded growth: $55.7M Q1 FCF and $138M cash allow capacity expansion without dilution at a depressed multiple
- Federal securities lawsuit (filed June 2026) alleging revenue inflation — existential risk if it leads to restatement or SEC enforcement
- Sequential revenue decline Q4 2025 → Q1 2026 (-17.7%, from $139.2M to $114.5M) suggests either seasonality or trend deterioration — needs confirmation Aug 5
- Recent EPS/sales surprises of -11.7%/-18.2% show consensus is still ahead of reality on execution
- Aug 5, 2026 earnings is a binary event with elevated gap risk given legal overhang and prior misses
- Technical structure severely broken: -38.5% below SMA200, -57.9% below 52-week high, 9.45% short interest and institutional transactions -4.52%
- Retail sentiment 83% bullish while institutions are reducing — recurring contrarian signal on this ticker
- Long-term plasma-derived therapeutics face substitution risk from recombinant/synthetic biologics
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord